Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding

Annals of Internal Medicine

Volumn 150, Issue 6, 2009, Pages 379-386

  Steinhubl, Steven R ^{a,b,c,d,e,f,g,h}   Bhatt, Deepak L ^b   Brennan, Danielle M ^c   Montalescot, Gilles ^d   Hankey, Graeme J ^e   Eikelboom, John W ^f   Berger, Peter B ^g   Topol, Eric J ⁱ  

^a Geisinger Clinic   (United States)

^b Medicines Company   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ROYAL PERTH HOSPITAL   (Australia)

^g MCMASTER UNIVERSITY   (Canada)

^h SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

ⁱ GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PLACEBO;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 62549138243     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-6-200903170-00006     Document Type: Article

References (28)

1. U.S. Food and Drug Administration. Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination With Antacid Drug Products. Accessed at www.fda.gov/ohrms/dockets/98fr//102398c.txt on 22 January 2009.
2. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-84. [PMID: 3933848]
3. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30:74-7. [PMID: 16414427]
4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15-9. [PMID: 15231615]
5. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. [PMID: 16987411]
6. Ng W, Wong WM, Chen WH, Tse HF, Lee PY, Lai KC, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol. 2006;12:2923-7. [PMID: 16718820]
7. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004;43:972-8. [PMID: 15028352]
8. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, nternational trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406. [PMID: 12874182]
9. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-7. [PMID: 14504182]
10. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17. [PMID: 16531616]
11. An international randomized trial comparing four thrombolytic strategies foracute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329:673-82. [PMID: 8204123]
12. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56:3014-9. [PMID: 17848625]
13. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37:2153-8. [PMID: 16794200]
14. Gibson PC. Aspirin in the treatment of vascular diseases. Lancet. 1949;2: 1172-4. [PMID: 15408149]
15. Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, et al. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation. 1991;84:2054- 62. [PMID: 1934381]
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. [PMID: 11786451]
17. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018- 24. [PMID: 17488967]
18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-286. [PMID: 16490830]
19. Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med. 1994;120:184-9. [PMID: 8273981]
20. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827- 30. [PMID: 7711618]
21. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218-22. [PMID: 15877994]
22. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983; 71:676-88. [PMID: 6338043]
23. Rao SV. Bleeding as a predictor of mortality risk. Rev Cardiovasc Med. 2006;7 Suppl 3:S12-8. [PMID: 17224879]
24. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175-8. [PMID: 14671242]
25. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153:175-81. [PMID: 17239674]
26. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-5. [PMID: 11940542]
27. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118:1705-12. [PMID: 18838564]
28. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-5. [PMID: 10952950]